Jefferies Financial Group began coverage on shares of Kalvista Pharmaceuticals (NASDAQ:KALV) in a report released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $30.00 target price on the specialty pharmaceutical company’s stock. Jefferies Financial Group also issued estimates for Kalvista Pharmaceuticals’ Q2 2019 earnings at ($0.37) EPS, Q3 2019 earnings at ($0.61) EPS, Q4 2019 earnings at ($0.46) EPS, FY2019 earnings at ($1.92) EPS, FY2020 earnings at ($1.88) EPS, FY2021 earnings at ($4.00) EPS, FY2022 earnings at $0.51 EPS and FY2023 earnings at ($0.24) EPS.
KALV has been the subject of a number of other research reports. Zacks Investment Research raised Kalvista Pharmaceuticals from a hold rating to a buy rating and set a $19.00 price objective for the company in a research note on Wednesday, September 12th. ValuEngine raised Kalvista Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 2nd. BidaskClub raised Kalvista Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Friday, October 19th. Roth Capital began coverage on Kalvista Pharmaceuticals in a research note on Tuesday, July 10th. They issued a buy rating and a $20.00 price target for the company. Finally, Stifel Nicolaus began coverage on Kalvista Pharmaceuticals in a research note on Monday, October 15th. They issued a buy rating for the company. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Kalvista Pharmaceuticals currently has a consensus rating of Buy and an average target price of $25.25.
NASDAQ:KALV opened at $19.79 on Tuesday. The company has a market cap of $324.68 million, a PE ratio of -12.93 and a beta of 2.86. Kalvista Pharmaceuticals has a fifty-two week low of $7.73 and a fifty-two week high of $23.97.
Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.14). The company had revenue of $3.72 million for the quarter, compared to analysts’ expectations of $4.11 million. Kalvista Pharmaceuticals had a negative net margin of 132.38% and a negative return on equity of 56.24%. As a group, sell-side analysts forecast that Kalvista Pharmaceuticals will post -2.07 EPS for the current year.
In other Kalvista Pharmaceuticals news, Director Albert Cha purchased 1,058,824 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was bought at an average price of $17.00 per share, with a total value of $18,000,008.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 49.10% of the company’s stock.
A number of hedge funds have recently made changes to their positions in KALV. Wedge Capital Management L L P NC purchased a new stake in Kalvista Pharmaceuticals in the third quarter worth $1,492,000. Interwest Venture Management Co. raised its holdings in Kalvista Pharmaceuticals by 17.8% in the third quarter. Interwest Venture Management Co. now owns 388,766 shares of the specialty pharmaceutical company’s stock worth $8,596,000 after purchasing an additional 58,824 shares in the last quarter. Wells Fargo & Company MN bought a new position in Kalvista Pharmaceuticals in the third quarter worth $598,000. Stanley Laman Group Ltd. raised its holdings in Kalvista Pharmaceuticals by 48.3% in the second quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock worth $545,000 after purchasing an additional 21,861 shares in the last quarter. Finally, Spark Investment Management LLC bought a new position in Kalvista Pharmaceuticals in the second quarter worth $108,000. 37.12% of the stock is owned by institutional investors.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Read More: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.